Short stature and growth hormone use in pediatric hemodialysis patients

End-stage renal disease (ESRD) causes growth retardation in children, and poor growth has been linked to worse outcomes. Recombinant human growth hormone (rhGH) can increase growth velocity and final adult height in pediatric ESRD patients. We aimed to identify clinical predictors of short stature (height standard deviation score (Ht SDS) <-1.88) and rhGH use in short stature pediatric hemodialysis patients. In 2002, the Centers for Medicare & Medicaid Services (CMS) Clinical Performances Measures (CPM) ESRD Project collected demographic, clinical and laboratory data as well as rhGH use on all in-center hemodialysis patients in the US aged <18 years. The odds ratios (OR) of short stature and rhGH use for individual predictors were determined by multivariate logistic regression modeling. Six-hundred and fifty-one (92%) of 710 eligible patients were included for analysis. Of these, 266 (41%) had Ht SDS <-1.88. After adjustment, short stature was predicted by congenital/urologic causes of ESRD ((OR 5.4; 95% confidence interval [CI], 2.1-13.8; p <0.001) in patients aged 10-14 years; (OR 2.8; 95% CI, 1.5-5.4; p <0.01) in patients aged 15-18 years) and increasing years on dialysis ((OR 1.2; 95% CI, 1.1-1.4; p <0.01) in patients aged 10-14 years; (OR 1.2; 95% CI, 1.1-1.4; p <0.001) in patients aged 15-18 years). Of 266 short stature patients, 214 (80.5%) had data on rhGH use. Of these, 80 (37%) had been prescribed rhGH. After adjustment, use of rhGH in short-stature patients was predicted by white race (OR 2.1; 95% CI, 1.1-4.0; p <0.05), increasing years on dialysis (OR 1.13; 95% CI, 1.05-1.22; p <0.01) and patients with BMI <16.6 kg/m(2) (OR 3.1; 95% CI, 1.2-8.4; p <0.05). Increasing age and level of intact parathyroid hormone were not associated with rhGH use among short stature patients. A significant proportion of pediatric hemodialysis patients have short stature. The majority of short-stature patients are not receiving rhGH. Patients with short stature who are white, have longer durations on dialysis and have lower BMI are more likely to receive rhGH.     

Vascular access complications in long-term pediatric hemodialysis patients

Current data demonstrate pediatric patients who remain on hemodialysis (HD) therapy are more likely to be dialyzed via central venous catheters (CVCs) than arteriovenous grafts (AVGs) and fistulae (AVFs). We retrospectively compared complications and health-related quality of life (HRQOL) associated with different vascular access types at two large centers over a 1-year period. Patients included in the study were younger than 25 years of age, weighed >20 kg, and had received HD for at least 3 months. Thirty CVC patients and 21 AVG/AVF patients received a total of 2,393 and 3,506 HD treatments, respectively. The infectious complication rate was higher for CVC patients, who were hospitalized 3.7 days for each 100 HD treatments versus 0.2 days for AVG/AVF patients (p < 0.01). CVC patients also had a much higher rate of access revision, needing 2.7 hospital days every 100 HD treatments compared with 0.2 days for AVG/AVF patients (p < 0.01). HRQOL scores did not differ between groups. Thus, despite similar HRQOL, CVCs were associated with more complications and greater morbidity when compared with AVG/AVFs. These findings further emphasize the need to use AVG/AVFs as primary HD access for pediatric patients expected to receive a long course of maintenance HD.     

Deferoxamine and aluminum clearance in pediatric hemodialysis patients

Mobilization of aluminum by deferoxamine and the subsequent clearance from plasma by hemodialysis with or without charcoal hemofiltration was studied in four pediatric patients. Deferoxamine, 10–20 mg/kg, followed by dialysis with a Travenol CA50 dialyzer produced reductions in mean plasma aluminum levels from 2433±729 nmol/l (65.5±19.6 g/l) to 1727±554 nmol/l (46.5±14.9 g/l) during dialysis. The use of a charcoal cartridge in the circuit resulted in a reduction in mean plasma aluminum levels 2459±591 nmol/l (66.2±15.9 g/ml) to 1380±106 nmol/l (35.8±2.9 g/l). In one patient, high-flux dialysis produced a reduction from 2140 nmol/l (55.6 g/l) to 1134 nmol/l (29.4 g/l). No patients suffered direct adverse reactions to low-dose deferoxamine, although two patients had previously exhibited potential aluminum neurotoxicity after rapid increases in plasma aluminum levels with deferoxamine in higher doses. Aluminum levels must be monitored closely during deferoxamine therapy in uremic children to minimize the risk of exacerbating aluminum neurotoxicity.     

Maintenance intravenous iron therapy in pediatric hemodialysis patients

Iron supplementation is required for optimal response to erythropoietin (EPO) in hemodialysis patients. This is due to blood lost in the dialysis tubing after dialysis and the increased demand for iron by EPO therapy. Maintenance intravenous (IV) iron was administered according to a standardized protocol to pediatric patients on hemodialysis in our institution. The effect of this protocol on EPO dose, iron indices, anemia, and medication costs was evaluated. Data on two groups of patients were retrieved from the health records. Group 1 (n=14) consisted of patients treated in the 18 months prior to the protocol. These patients received oral iron supplements and occasional IV iron. Group 2 (n=5) consisted of all patients treated with the IV iron protocol. There was no difference in clinical characteristics and mean values for monthly hemoglobin, serum iron, ferritin, and transferrin saturation between groups. The dose of EPO was significantly reduced in group 2 compared with group 1 (193.9±121.4 vs. 73.9±39.0 units/kg per week, P<0.05). Medication costs were reduced by 26% in group 2. No significant adverse events were seen. Maintenance IV iron reduced the dose of EPO required to maintain blood hemoglobin levels. Our results also suggest that maintenance IV iron is a more-economic method of iron supplementation for pediatric hemodialysis patients. Received: 13 November 2000 / Revised: 23 April 2001 / Accepted: 24 April 2001     

Recombinant human growth hormone treatment of children on hemodialysis

Forty-two children, aged 2–21.5 years on hemodialysis with a height below –2.0 standard deviation score (SDS) for age, were selected to receive recombinant human growth hormone (rhGH) therapy at 17 French centers. Of the 42 children, 36 were prepubertal and 8 were in early puberty (testicular volume between 4 and 8 ml for boys, breast development B2 or B3 in girls). All received 1 IU/kg per week by daily subcutaneous injection for 1–5 years. The year before rhGH therapy served as a control period. During the 1st year of treatment, mean growth velocity increased from 3.5 to 7.0 cm/year (P <0.0001) and was always over 2.5 cm/year. This velocity allowed a catch-up growth of +0.5 height SDS. Neither weight nor the body mass index varied compared with the pretreatment year. No change was observed in urea, creatinine, or glucose tolerance. The mean increment in bone age was 0.9 years. The mean growth velocity decreased over subsequent years (P <0.0001), but remained higher than the prestudy velocity. A significant negative correlation was observed during the 1st year between the increase in growth velocity and the prestudy velocity (P <0.0001), with the least gain in patients who had the best spontaneous velocity. Pubertal status had no influence on response to rhGH. No significant side effects were observed during the 103 treatment-years. Five patients developed secondary hyperparathyroidism and 1 suffered from acute pancreatitis, but the relationship with rhGH therapy remains uncertain. rhGH therapy appears indicated for children on hemodialysis, even though the potential benefits appear somewhat lower for those with a spontaneous growth velocity over 6 cm/year. Received April 18, 1997; received in revised form October 23, 1997; accepted October 28, 1997     

Vancomycin prevents polytetrafluoroethylene graft infections in pediatric patients receiving chronic hemodialysis

Polytetrafluoroethylene (PTFE) grafts have been a useful addition to the pediatric hemodialysis vascular access armamentarium. In this study, 17 pediatric patients underwent 331 total months of hemodialysis via PTFE grafts. There was a statistically significant (P less than .025) decrease in the incidence of graft infections in 12 patients (235 patient-months) while receiving prophylactic parenteral vancomycin compared with 9 patients (96 patient-months) while receiving no vancomycin (0% v 44%). Vancomycin side effects were uncommon and mild. Vancomycin is a safe and effective agent for the prevention of PTFE graft infections in pediatric patients receiving chronic hemodialysis.     

Intravenous iron therapy in pediatric hemodialysis patients: a meta-analysis

Dialysis guidelines recommend aggressive management of anemia, including the use of intravenous iron (IVFe) when indicated. However, few published data are available to guide the use of IVFe in children, and studies are difficult to compare. In this meta-analysis we sought to combine evidence by pooling clinical trial data to determine if IVFe therapy helped increase hematocrit, serum levels of hemoglobin, ferritin, and transferrin saturation (TSAT), and reduce erythropoietin use. We searched MEDLINE and other databases, publications, and other sources to identify as many published and unpublished trials as possible. Of 379 possible studies, nine met the criteria for inclusion and analysis. Across all nine studies, 141 patients were studied, for durations of 2 weeks to 12 months. Pooled results identified an increase in hemoglobin, hematocrit, ferritin, and TSAT levels, and reduced use of erythropoietin, with effect sizes (in standardized weighted mean differences) ranging from 0.62 (95% confidence interval 0.11–1.13) to 1.86 (1.58–2.15) standard deviation improvements. Current practice is based largely on extrapolation from adult data and a few small pediatric trials. The pooled pediatric data suggest that IVFe is effective and produces moderate to large effects on the reported outcomes. Prospective, multi-center trials are needed to determine the optimal utilization of IVFe in children.     

Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients

Secondary hyperparathyroidism (SHPT) remains a treatment dilemma in pediatric dialysis patients. Recent experience with paricalcitol (P), a vitamin D analogue, in adults with SHPT has shown equal efficacy and improved survival compared to traditional treatment with calcitriol (C). We present our experience with (C) compared to (P) treatment in our pediatric dialysis patients with SHPT. Twenty-one patients (mean age 11.5±5 years) with SHPT (intact parathyroid hormone (iPTH) averaging 1,228±496 pg/ml) were studied. Seventeen received (C) followed by (P); while an additional four were treated with either (C=1) or (P=3) alone. After 26±8 weeks, average percent (%) decrease in iPTH was similar with (C) and (P) (−60.4±34% versus −65.4±28%, respectively; p=0.6). In the (P) group, the effective dose in children was greater than in adult trials based on kilogram weight. Episodes of hypercalcemia between the treatment groups were not different. However, episodes of elevated calcium × phosphorus product (Ca×P)≥70 mg²/dl² occurred more frequently in the (C) group (odds ratio=1.5; p=0.01). Paricalcitol appears to be safe and effective in pediatric patients. Data suggest that dosing should be gauged according to degree of SHPT. This should serve as impetus for future pharmacokinetic studies in pediatric dialysis patients.     

Longitudinal analysis of intermediate outcomes in adolescent hemodialysis patients

In 2000 and 2001, The Centers for Medicare & Medicaid Services (CMS) End-Stage Renal Disease (ESRD) Clinical Performance Measures (CPM) project collected data on all in-center hemodialysis (HD) patients in the United States aged >or=12 and <18 years. There were 433 of 486 (89%) patients and 435 of 516 (84%) patients who had the minimum required data submitted and were included in the 2000 and 2001 study years, respectively. There were 188 patients (43%) who had data submitted in both study years, providing longitudinal data on this cohort. A comparison of clinical parameters on these 188 patients in the 2000 and 2001 study years reveals significant improvement in mean calculated spKt/V (1.50+/-0.36 vs. 1.58+/-0.30, P<0.01), mean hemoglobin (11.0+/-1.6 g/dl vs. 11.5+/-1.3 g/dl, P<0.001), mean ferritin (286+/-278 ng/ml vs. 460+/-353 ng/ml, P<0.001), mean transferrin saturation (27.8+/-15.1% vs. 31.3+/-15.0%, P<0.05), mean serum albumin as measured by the bromocresol green method (3.83+/-0.54 g/dl vs. 3.95+/-0.42 g/dl, P<0.01), and mean height standard deviation score (-1.814+/-1.756 vs. -1.699+/-1.657, P<0.05). In addition, 20 of 29 (69%) patients who had a spKt/V <1.2 in the 2000 study year had a spKt/V >1.2 in the 2001 study year. Of 68 (44%) patients who had a catheter as their HD access in the 2000 study year, 30 had an arteriovenous fistula or graft in the 2001 study year and 49 of 80 (61%) patients who had a mean hemoglobin <11 g/dl in the 2000 study year had a hemoglobin >11 g/dl in the 2001 study year. In summary, these longitudinal data demonstrate significant improvements in nearly all clinical parameters studied in these adolescent HD patients.     

Growth in adolescent hemodialysis patients: Data from the Centers for Medicare & Medicaid Services ESRD Clinical Performance Measures Project

The Centers for Medicare & Medicaid Services' (CMS) end-stage renal disease (ESRD) Clinical Performance Measures (CPM) Project has collected data on all adolescent hemodialysis patients since 2000. Thus, by 2002 data were available on all adolescents on hemodialysis in the USA for 3 consecutive years. Possible associations between clinical parameters and linear growth in this cohort were evaluated. Ninety-four adolescents were on hemodialysis for the 3 study years. The mean height standard deviation score (ht SDS) fell from -1.97 to -2.36 over the 3 study years. Compared with patients with ht SDS > or =-1.88, patients with ht SDS <-1.88 in the 2002 study year (n =53) were more likely to be male (66% vs 44%, p <0.05), on dialysis longer (6.9+/-4.5 years vs 4.1+/-2.3 years, p <0.001), and had lower height SDS in the 2000 study year (-2.90+/-1.31 vs -0.772+/-1.10, p <0.001). Patients with a ht SDS <-1.88 had a lower mean hemoglobin (11.4+/-1.6 g/dl vs 12.0+/-1.1 g/dl, p <0.05), but there were no differences in other clinical parameters. Among patients with ht SDS <-1.88, 38.8% (n =20) were prescribed recombinant human growth hormone (rhGH) in the 2002 study year. There were no differences in demographic or clinical parameters between rhGH treated and untreated patients. Many adolescents who remain on hemodialysis have poor linear growth. Further evaluation is needed to delineate contributory factors and the possible underutilization of rhGH.     

Sodium ferric gluconate complex therapy in anemic children on hemodialysis

Pediatric patients with end-stage renal disease undergoing hemodialysis (HD) frequently develop anemia. Administration of recombinant human erythropoietin (rHuEPO) is effective in managing this anemia, although the additional demand for iron often results in iron deficiency. In adult patients undergoing HD, intravenous (IV) iron administration is known to replenish iron stores more effectively than oral iron administration. Nevertheless, IV iron supplementation is underutilized in pediatric patients, possibly because of unproved safety in this population. This international, multicenter study investigated the safety and efficacy of two dosing regimens (1.5 mg kg^–1 and 3.0 mg kg^–1) of sodium ferric gluconate complex (SFGC) therapy, during eight consecutive HD sessions, in iron-deficient pediatric HD patients receiving concomitant rHuEPO therapy. Safety was evaluated in 66 patients and efficacy was evaluated in 56 patients. Significant increases from baseline were observed in both treatment groups 2 and 4 weeks after cessation of SFGC dosing for mean hemoglobin, hematocrit, transferrin saturation, serum ferritin, and reticulocyte hemoglobin content. Efficacy and safety profiles were comparable for 1.5 mg kg^–1 and 3.0 mg kg^–1 SFGC with no unexpected adverse events with either dose. Administration of SFGC was safe and efficacious in the pediatric HD population. Given the equivalent efficacy of the two doses, an initial dosing regimen of 1.5 mg kg^–1 is recommended for pediatric HD patients.An erratum to this article can be found at The Ferrlecit Pediatric Study Group is a co-author of this paper     

血液透析患者脂代谢紊乱的临床研究

目的探讨血液透析患者脂代谢紊乱的临床特征及原因。方法检测106例维持性血液透析患者空腹血脂,并对影响血脂水平及有关因素进行分析。结果血液透析患者脂代谢紊乱主要表现为血清甘油三脂（TG）、载脂蛋白B（Apo-LB）水平显著增高,高密度脂蛋白胆固醇（HDLC）显著降低。TG与血清白蛋白（Alb）、透析时体外循环血流量显著负相关（r=-0．398,r=-0．219）;HDLC水平与Kt／V显著相关（r=-0．305）。血液透析患者高血压的发生率为73．6％,心血管病变为25％。伴心血管疾病的血液透析患者TG水平显著高于无心血管疾病者。结论血液透析患者脂代谢紊乱主要表现为TG、Apo-LB水平增高,HDLC水平降低。透析充分及透析时体外循环血流量及血清白蛋白水平影响血脂水平。     

高通量透析对尿毒症维持性血液透析患者血管内皮功能的影响

目的 探讨高通量血液透析( high-flux hemodialysis,HFHD)对尿毒症维持性血液透析患者血管内皮功能的影响.方法 采用自身对照研究,选取33例维持性常规低通量血液透析的尿毒症患者,接受HFHD治疗6个月.治疗前(0个月)及治疗6个月分别采血测定血脂、白介素-6(IL-6)、超敏C反应蛋白(hsCRP)、糖基化终末产物(AGEs)和β2-微球蛋白(β2-MG)水平,同时采用高分辨血管外超声检测肱动脉血流介导的内皮依赖性血管舒张功能( flow-mediated dilation FMD).分析比较HFHD对上述指标的影响及其相关性.结果 HFHD治疗后,患者高密度脂蛋白升高、胆固醇及低密度脂蛋白水平下降,IL-6、32-MG、AGEs水平降低,均具有统计学差异;FMD较治疗前有上升趋势(6.61％±4.93％,6 85％±4.4％),但无统计学意义;相关性分析显示FMD与高密度脂蛋白呈正相关,与β2-MG呈负相关(r值分别为0.323和-0.328,P＜0.05).结论 HFHD可改善尿毒症维持性血液透析患者脂质代谢,升高高密度脂蛋白,降低胆固醇和低密度脂蛋白;同时增加炎症介质,糖基化终末产物及β2-微球蛋白的清除;HFHD能够延缓血液透析患者血管内皮功能损伤,可能与有效清除炎症介质,降低氧化应激和改善脂质代谢相关.     

Bacteremia in a pediatric hemodialysis unit secondary toEnterococcus fecalis

Bacteremia is often a serious and recurring problem in children with hemodialysis catheters. We report an outbreak ofEnterococcus bacteremia in a pediatirc hemodialysis unit occurring from June 1992 to June 1993. During this period, 18 episodes of bacteremia occurred in eight children: 11 infections were polymicrobial.Enterococcus fecalis was associated with 13 infections in five patients (8 polymicrobial). Other pathogens includedEnterobacter cloacae (5 infections),Staphylococcus (3),Staphylococcus epidermidis (2), andKlebsiella pneumoniae (2). AllEnterococcus infections occurred in patients with dual-lumen subclavian venous catheters. Skin and catheter sites were culture negative, except in one patient. Rectal swabs were positive forEnterococcus in five patients.Enterococcus was not isolated from any source within the unit. Serotypes of allEnterococcus isolates were different, except for 2 isolates in the same patient. Starting in June 1993, catheters were flushed after dialysis with vancomycin or ampicillin. Since initiating this procedure, further episodes ofEnterococcus bacteremia have not occurred. A questionnaire sent to other pediatric hemodialysis units failed to identifyEnterococcus among 26 cases of bacteremia. In conclusion: (1)Enterococcus is an unusual pathogen for hemodialysis-related bacteremia in children; (2) patients with dialysis catheters were predisposed to this infection; (3) a common source forEnterococcus could not be identified by either culture or by serotyping; (4) flushing catheters with antibiotics after dialysis was effective prevention.     

维持性血透患者的心理状态研究

研究我国血透患者的心理状况并进行针对性的心理治疗。方法 采用症状自评量表(SCL90-R)、多维度健康状况心理控制源量表(MHLC)、艾森克个性问卷(EPQ)及终末期肾脏病(ESRD)患者专用的生活质量表对北京六个医院透析中心的92名维持性血透患者进行了心理状态的研究,并与美国及加拿大相同的研究进行了比较分析。结果 本组的血透存在着抑郁、焦虑、恐怖等心理障碍,出现心理障碍的比例显著高于美国同类患者(P<0.01),且焦虑的发生率高于美国同类患者(P<0.01)。这些障碍与MHLC中机遇项分(CED)显著相关(P<0.01)。EPQ中神经质项分高者倾向于发生抑郁、焦虑等心理障碍。本组的血透患者客观生活质量较加拿大同类患者低(P<0.01),但在总的生活满意度上没有显著性差异。生活质量与心理及躯体因素均呈显著相关,心理障碍与躯体症状也显著相关(P<0.01)。结论 本组的血透患者心理状态与美国加拿大同类患者相比既有相同之处,又有特殊之处。我们应该兼顾病人的躯体和精神两方面的健康,努力提高他们的生活质量。     

Iron therapy in the pediatric hemodialysis population

Iron therapy maintains iron stores and optimizes the response to recombinant human erythropoietin (r-HuEPO) in patients with end-stage renal failure. Information is limited, however, regarding the preferential route of iron administration in pediatric patients receiving hemodialysis. Therefore, we prospectively randomized 35 iron-replete patients (aged >1 to <20 years) to receive up to 16 weeks of maintenance IV (n=17) or daily oral (n=18) iron. Eligible patients had received hemodialysis for >2 months, had a baseline transferrin saturation [TSAT] >20%, and were receiving maintenance r-HuEPO. Treatment arms were evenly distributed with respect to baseline demographic and clinical characteristics, with no statistically significant differences in baseline hemoglobin (Hb), hematocrit (Hct), reticulocyte Hb content (CHr), serum ferritin (SF), TSAT, or r-HuEPO dose. In the 35 patients, IV iron dextran and not oral iron was associated with a significant increase (138.5 to 259.1 ng/ml, P=0.003) in SF. A comparison of the change in SF between the IV iron group and the oral iron group was also significant (P=0.001). Whereas only IV iron was associated with a significant decrease in the dose of r-HuEPO (234.0 to 157.6 U/kg per week, P=0.046) and an increase of the CHr (29.2 to 30.1 pg, P=0.049), these changes were not significantly different from those experienced by patients in the oral iron group. In both groups, the Hct remained stable and in neither group was there a significant change in the TSAT. In summary, although both oral and IV iron maintained patients in an iron-replete state in this short-term study, only IV therapy allowed for a significant improvement in iron stores.     

维持性血液透析患者动脉粥样硬化的早期诊断及相关因素研究

显著的影响.MHD患者桡动脉内膜厚度显著厚于对照组(P＜0.05),与颈动脉IMT呈正相关(P＜0.01).有斑块患者IMT及心血管并发症的发生率高于无斑块患者(P＜0.01).结论 MHD患者颈动脉粥样硬化发生率高,微炎症状态是其发生的重要影响因素.     

维持性血液透析后血清尿素反弹及其影响因素

目的 研究观察维持性血液透析（MHD）患者透析后血清尿素反弹情况及相关影响因素。 方法 稳定的MHD患者124例为对象。取透析前、透析结束时、透析后15 min、30 min血样，定量观察尿素反弹及其对透析充分性指标单室尿素清除指数（spKt/V）和血清尿素下降率（URR）的影响。分析其与患者人口学特征、透析参数的相关关系。 结果 血液透析后的血清尿素反弹平均达13.6%，导致URR和spKt/V分别高估0.04和0.14。影响尿素反弹最重要的因素是透析效率K/V，此外还有较高的血红蛋白、较多的相对超滤量、动静脉通路和男性。 结论 血液透析后的尿素反弹普遍存在。对于特定的个体和透析过程，其对透析充分性指标的影响不能忽略。     

Pylorus-preserving pancreaticoduodenectomy in patients undergoing chronic hemodialysis

This report describes three patients who underwent a pylorus-preserving pancreaticoduodenectomy (PpPD) and received maintenance hemodialysis due to chronic renal failure. The three cases were diagnosed to have bile duct cancer, intraductal papillary mucinous neoplasm, and carcinoma of the ampulla of Vater, respectively. They underwent chronic hemodialysis for 7.7 years. They all underwent a PpPD with lymph node dissection. The mean operation time was 373 min and mean blood loss was 647 ml. During the postoperative courses, hemodialysis was restarted on postoperative day 1 in all three cases. In the three patients, only minor complications were experienced and these were treated conservatively. The mean postoperative hospital stay was 48 days. Two patients are still alive 135 and 21 months after the operation, respectively, but the other patient died of another disease 21 months after the PpPD. A PpPD may therefore be safe and feasible even in patients receiving chronic hemodialysis.     

维持性血液透析患者抑郁状态的相关因素分析

目的调查抑郁状态在维持性血液透析（maintenancehemodialysis,MHD）患者中的发生情况,探讨与抑郁相关的生理及社会因素,为进一步的心理干预做好前期工作。方法采用横断面调查,应用Zung抑郁自评量表对太仓市第一人民医院血液净化中心的102例MHD患者进行评估,根据患者是否合并抑郁状态分为非抑郁组（36例）和抑郁组（66例）。收集MHD患者的个人背景资料、临床资料、实验室数据以及问卷调查结果（以社会支持评定量表评分评估患者的社会支持程度,以营养不良-炎症评分评估患者的营养水平,以Charlson评分评估患者的合并症严重程度）,采用SPSS13．0软件进行统计分析,探讨与抑郁状态相关的因素。结果102例MHD患者中,合并抑郁症的患者66例,发生率为64．7％,仅6例（占9％）的抑郁症患者曾主动寻求过医疗帮助。非抑郁组与抑郁组比较,年龄、营养不良一炎症评分、Charlson指数、C反应蛋白水平偏低（P〈0．05）,而血白蛋白、社会支持评定量表评分、收入情况、有配偶的比例较高（P〈0．05）。进一步行多重线性回归分析发现,年龄、收入情况、Charlson指数、C反应蛋白均可独立的在不同程度上影响Zung抑郁自评量表评分,收入情况为影响Zung抑郁自评量表评分的最主要因素。结论MHD患者的抑郁症发病率较高,主动求医率低,年龄、收入水平、合并症的严重程度、C反应蛋白均为影响MHD患者抑郁程度的独立危险因素,而收入情况可能对抑郁程度的影响最大。